| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | B3GNT6 |
| Uniprot No | Q6ZMB0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-384aa |
| 氨基酸序列 | MAFPCRRSLTAKTLACLLVGVSFLALQQWFLQAPRSPREERSPQEETPEGPTDAPAADEPPSELVPGPPCVANASANATADFEQLPARIQDFLRYRHCRHFPLLWDAPAKCAGGRGVFLLLAVKSAPEHYERRELIRRTWGQERSYGGRPVRRLFLLGTPGPEDEARAERLAELVALEAREHGDVLQWAFADTFLNLTLKHLHLLDWLAARCPHARFLLSGDDDVFVHTANVVRFLQAQPPGRHLFSGQLMEGSVPIRDSWSKYFVPPQLFPGSAYPVYCSGGGFLLSGPTARALRAAARHTPLFPIDDAYMGMCLERAGLAPSGHEGIRPFGVQLPGAQQSSFDPCMYRELLLVHRFAPYEMLLMWKALHSPALSCDRGHRVS |
| 分子量 | 69.1 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 冻干粉 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于B3GANT6(B3GNT6)的文献示例，内容基于真实研究主题概括，文献名称与作者为虚构模拟(仅供参考)：
1. **文献名称**：*B3GNT6-mediated glycosylation in colorectal cancer metastasis*
**作者**：Zhang et al. (2018)
**摘要**：研究发现B3GNT6通过调控黏蛋白O-糖基化修饰，促进结肠癌细胞黏附与转移，靶向抑制B3GNT6可减少体内外肿瘤侵袭能力。
2. **文献名称**：*B3GNT6 regulates T cell immunity via CD28 co-stimulatory signaling*
**作者**：Lee et al. (2020)
**摘要**：揭示了B3GNT6在T细胞活化中的作用，其通过修饰CD28的糖链结构影响T细胞受体信号传导，敲除后导致小鼠免疫应答降低。
3. **文献名称**：*Structural and functional analysis of B3GNT6 in poly-N-acetyllactosamine synthesis*
**作者**：Taniguchi et al. (2016)
**摘要**：解析了B3GNT6的晶体结构，阐明其催化合成poly-LacNAc糖链的分子机制，为糖基转移酶家族功能研究提供新依据。
4. **文献名称**：*B3GNT6 as a biomarker for inflammatory bowel disease progression*
**作者**：Wang et al. (2021)
**摘要**：临床数据表明，B3GNT6在炎症性肠病患者肠道组织高表达，其介导的糖基化异常可能参与肠黏膜屏障破坏及炎症恶化。
**注意**：以上文献信息为示例性模拟，实际研究需通过学术数据库(如PubMed、Web of Science)检索真实文献。
B3GNT6 (β-1.3-N-Acetylglucosaminyltransferase 6) is a glycosyltransferase belonging to the β3GnT family, which catalyzes the synthesis of poly-N-acetyllactosamine (poly-LacNAc) chains. These carbohydrate structures are critical for cell-cell interactions, immune responses, and signal transduction. B3GNT6 specifically transfers N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to galactose residues in a β1.3-linkage, extending glycan chains on glycoproteins and glycolipids. It is encoded by the B3GNT6 gene located on human chromosome 11q13.4 and features a type II transmembrane protein structure with a short cytoplasmic tail.
Research highlights its role in leukocyte trafficking by synthesizing functional L-selectin ligands, particularly in neutrophils, facilitating their adhesion to endothelial cells during inflammation. Dysregulation of B3GNT6 is implicated in pathological processes, including cancer progression and metastasis. Elevated B3GNT6 expression in certain tumors correlates with enhanced invasiveness, potentially through modifying glycans involved in cell migration or immune evasion. Additionally, genetic variants of B3GNT6 are linked to inflammatory bowel disease (IBD), suggesting its involvement in mucosal immunity.
Recombinant B3GNT6 is widely used in vitro to study glycan biosynthesis, enzyme kinetics, and structure-function relationships. Its applications extend to exploring therapeutic targets for cancer and inflammatory disorders. Despite progress, mechanisms underlying its tissue-specific regulation and disease-associated roles remain under investigation, highlighting the enzyme’s biological and clinical relevance.
×
